Plasma Oxytocin in Response to Oral Estradiol Valerate and Ethinylestradiol in Healthy Controls and Patients With AVP-Deficiency
The PHOENIX study aims to investigate whether oral estradiol valerate (EV) and ethinylestradiol (EE) can stimulate oxytocin (OXT) and neurophysin-1 (NP-1) release in humans. The goal is to assess their potential as a safe diagnostic stimulation test for oxytocin deficiency, particularly in patients with arginine vasopressin (AVP) deficiency.
⁃ Part 1
• Adult healthy controls
• No medication (including hormonal contraception)
• Female patients (except post-menopausal): regular cycle (21-35 days of duration) in the last 6 months
⁃ Part 2
• Confirmed diagnosis of AVP-Deficiency
• Age ≥ 18 years
• Female patients (except post-menopausal): regular cycle (21-35 days of duration) in the last 6 months or in the case of hormone replacement therapy, with a 1-week pause from the respective treatment